Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44402   clinical trials with a EudraCT protocol, of which   7413   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,402 result(s) found. Displaying page 1,786 of 2,221.
    «« First « Previous 1782  1783  1784  1785  1786  1787  1788  1789  1790  Next» Last»»
    EudraCT Number: 2016-002036-32 Sponsor Protocol Number: C3441006(MDV3800-06) Start Date*: 2016-12-05
    Sponsor Name:Pfizer Inc.
    Full Title: TALAPRO 1: A PHASE 2, OPEN LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE BASED CHEMOTHE...
    Medical condition: Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) ES (Ongoing) FR (Completed) BE (Completed) GB (Completed) AT (Completed) DK (Prematurely Ended) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002498-36 Sponsor Protocol Number: CCN017 Start Date*: 2018-10-12
    Sponsor Name:National Institutes of Health - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Full Title: Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
    Medical condition: As the clinical trial is intended to investigate a new contraceptive medicinal product, the trial subjects included are not characterized by a specific medical condition.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10065589 Male contraception PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002104-12 Sponsor Protocol Number: FP2CLI004 Start Date*: 2021-09-08
    Sponsor Name:Faron Pharmaceuticals Ltd.
    Full Title: A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination with Standard of Care Therapy in Patients with Myelody...
    Medical condition: -Myelodysplastic Syndrome -Chronic Myelomonocytic Leukemia -Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002621-10 Sponsor Protocol Number: CA209-817 Start Date*: 2016-11-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with non-small cell lung cancer
    Medical condition: Non-Small cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) DE (Completed) NL (Completed) GR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) CZ (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-002937-31 Sponsor Protocol Number: MA30143 Start Date*: 2017-09-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) AT (Completed) DK (Completed) DE (Completed) PT (Completed) BE (Completed) HU (Completed) PL (Completed) SK (Completed) ES (Ongoing) BG (Completed) SI (Completed) NL (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002903-25 Sponsor Protocol Number: CC-4047-BRN-001 Start Date*: 2017-07-19
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.
    Medical condition: Recurrent or progressive primary brain tumors in one of four primary brain tumor types: high-grade glioma, medulloblastoma, ependymoma and diffuse intrinsic pontine glioma (DIPG
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003030-24 Sponsor Protocol Number: EDEN-GOIRC-04-2016 Start Date*: 2017-05-24
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: “An open-label, randomized phase III study of Early switch maintenance vs DElayed second-line Nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-l...
    Medical condition: Advanced stage (IIIB/IV) squamous non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025124 Lung squamous cell carcinoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025125 Lung squamous cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003097-41 Sponsor Protocol Number: EFC14335 Start Date*: 2017-02-20
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination with Pomalidomide and Low-dose Dexamethasone versus Pomalidomide and Low-dose Dexamethasone in Pa...
    Medical condition: Haematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) PT (Completed) ES (Completed) CZ (Completed) NO (Completed) GB (GB - no longer in EU/EEA) SK (Completed) BE (Completed) DK (Completed) FR (Ongoing) GR (Completed) DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003082-26 Sponsor Protocol Number: CA018-005 Start Date*: 2017-09-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma Master Protocol Amendment 07, dated 11-Jan-2022 SubProtoco...
    Medical condition: advanced renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003526-16 Sponsor Protocol Number: ACH471-101 Start Date*: 2018-07-20
    Sponsor Name:Alexion Pharmaceuticals Inc.
    Full Title: A Phase 2 Open-label Study of ACH-0144471 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005068-33 Sponsor Protocol Number: D4191C00068 Start Date*: 2017-08-28
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies
    Medical condition: The target patient population of the protocol includes patients with advanced solid tumors who meet the overall and tumor specific inclusion and exclusion criteria as outlined in each protocol Modu...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061272 Malignant urinary tract neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004734-22 Sponsor Protocol Number: WO39392 Start Date*: 2017-09-06
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/NAB-PACLITAXEL-BASED CHEMOTHERAPY COMPARED WI...
    Medical condition: Triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039850 Secondary malignant neoplasm of breast LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004986-18 Sponsor Protocol Number: DS8201-A-U201 Start Date*: 2017-11-08
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who are Resistant or Refrac...
    Medical condition: Unresectable/metastatic breast cancer with HER2 positive expression
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020826 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005112-17 Sponsor Protocol Number: IRFMN-BRC-7103 Start Date*: 2017-07-11
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Multicenter, randomized, phase II study of neoadjuvant chemotherapy associated or not with zoledronate and atorvastatin in triple negative breast cancers - YAPPETIZER Study
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004558-13 Sponsor Protocol Number: Z7224L02 Start Date*: 2017-05-30
    Sponsor Name:Zambon S.p.A.
    Full Title: A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin® (colistimethate sodium) in the treatment of sub...
    Medical condition: Non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) DE (Completed) PT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005189-75 Sponsor Protocol Number: BO39633 Start Date*: 2017-07-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY
    Medical condition: Cancer (Future parent protocols may include other cancer that are not included in this section)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) BE (Completed) FR (Trial now transitioned) NL (Ongoing) SI (Completed) PT (Completed) DE (Completed) LV (Prematurely Ended) LT (Ongoing) SK (Prematurely Ended) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000579-10 Sponsor Protocol Number: PEANUT Start Date*: 2019-03-20
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: An open label, single-arm, phase 2 study of pembrolizumab and nanoparticle albumin-bound paclitaxel in patients with metastatic urothelial carcinoma after chemotherapy failure; the PEANUT study
    Medical condition: Advanced or metastatic urothelial carcinoma of the bladder or urinary tract relapsed or refractory to chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000345-46 Sponsor Protocol Number: CRC2017_01 Start Date*: 2017-11-22
    Sponsor Name:CENTRO RICERCHE CLINICHE DI VERONA
    Full Title: A Phase II Study of Liposomial IrinoTecan (nal-IRI) with 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer ¿nITRo trial"
    Medical condition: Resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000845-39 Sponsor Protocol Number: FARM12LTAT Start Date*: 2017-05-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: THE ROLE OF ANTI TNF ALPHA AGENTS IN BEH¿ET¿S DISEASE REFRACTORY TO STANDARD OF CARE THERAPIES: MULTICENTER RANDOMIZED CONTROLLED PROSPECTIVE PARALLEL GROUP SINGLE-BLIND TRIAL TO EVALUATE THE 6 MON...
    Medical condition: BEH¿ET¿S DISEASE REFRACTORY TO STANDARD OF CARE THERAPIES
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10004215 Behcets disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000305-21 Sponsor Protocol Number: ASCB-Onco-2336-2017 Start Date*: 2017-10-20
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Assessment of bone response after LHRH-A and Enzalutamide plus minus Zoledronic Acid in prostate cancer patients with hormone sensitive metastatic bone disease: a prospectic, phase II, randomized, ...
    Medical condition: prostate cancer with hormone sensitive metastatic bone disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10036927 Prostate neoplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1782  1783  1784  1785  1786  1787  1788  1789  1790  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 08 12:29:06 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA